Advertisement
| direct observation therapy for tb: WHO consolidated guidelines on tuberculosis. Module 4 World Health Organization, 2022-04-30 Between 2011 and 2019, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO Consolidated Guidelines on Drug Resistant Tuberculosis Treatment, issued by WHO in March 2019. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development Groups, using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to summarize the evidence, and formulate policy recommendations and accompanying remarks. The present WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment includes a comprehensive set of WHO recommendations for the treatment and care of DR-TB. The document includes two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen (i.e. bedaquiline, pretomanid and linezolid). In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and MDR/RR-TB, including longer regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), the use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care. The guidelines are to be used primarily in national TB programmes, or their equivalents in Ministries of Health, and for other policy-makers and technical organizations working on TB and infectious diseases in public and private sectors and in the community. |
| direct observation therapy for tb: Treatment of Tuberculosis World Health Organization, 1993 |
| direct observation therapy for tb: Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care World Health Organization, 2017-06 The update of the Guidelines for Treatment of Drug-susceptible Tuberculosis and Patient Care is important in the context of the End TB Strategy, which recommends treatment and patient support for all people with TB. This update aims to use the best available evidence on the treatment of drug-susceptible TB and interventions to ensure adequate patient care and support in order to inform policy decisions made in these technical areas by national TB control program managers, national policy-makers, and medical practitioners in a variety of geographical, economic, and social settings. The objectives of these updated guidelines are to provide updated recommendations based on newly emerged evidence on the treatment of drug-susceptible TB and patient care as well as provide a summary of changes in the new guidelines with all the existing and valid WHO recommendations on the treatment of drug-susceptible TB and TB patient care. The key audience for these guidelines are policy-makers in ministries of health or managers of national TB programs who formulate country-specific TB treatment guidelines or who plan TB treatment programs. In addition, health professionals - including doctors, nurses, and educators working both in government services and nongovernmental organizations, such as technical agencies that are treating patients and organizing treatment services - will find these guidelines to be useful. |
| direct observation therapy for tb: Guidance on Ethics of Tuberculosis Prevention, Care and Control World Health Organization, 2015-04-20 With the growing breadth and complexity of TB efforts today comes a greater range of concerns associated with the ethics of action, inaction and specific approaches to clinical, public health and research interventions. In 2006, the documented emergence of extensively drug-resistant tuberculosis (XDR-TB),2 including a dramatic and lethal outbreak in South Africa, brought forward urgent issues of public health ethics given the imposition in some programs of involuntary detention of persons suspected and/or confirmed of being ill with drug-resistant TB under the justification of public safety. In a linked effort, the Stop TB Partnership agreed to establish a TB and Human Rights Task Force in 2010, with secretariat being provided by WHO and the Joint United Nations Program on HIV/AIDS (UNAIDS). The Task Force will aim to develop a policy framework for a rights-based approach to TB prevention, care and control as joint products of WHO, the Stop TB Partnership and UNAIDS. It will also propose a strategic agenda for action. It will be composed of major stakeholders, constituencies from affected communities and risk groups, human rights and civil society organizations, health and human rights experts, United Nations agencies, and development partners. This ethics guidance and the resulting rights-based policy framework will be used as complementary and companion documents to guide further dialogue and action in these areas. |
| direct observation therapy for tb: Disease Control Priorities, Third Edition (Volume 6) King K. Holmes, Stefano Bertozzi, Barry R. Bloom, Prabhat Jha, 2017-11-06 Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings. |
| direct observation therapy for tb: Disease Control Priorities in Developing Countries Dean T. Jamison, Joel G. Breman, Anthony R. Measham, George Alleyne, Mariam Claeson, David B. Evans, Prabhat Jha, Anne Mills, Philip Musgrove, 2006-04-02 Based on careful analysis of burden of disease and the costs ofinterventions, this second edition of 'Disease Control Priorities in Developing Countries, 2nd edition' highlights achievable priorities; measures progresstoward providing efficient, equitable care; promotes cost-effectiveinterventions to targeted populations; and encourages integrated effortsto optimize health. Nearly 500 experts - scientists, epidemiologists, health economists,academicians, and public health practitioners - from around the worldcontributed to the data sources and methodologies, and identifiedchallenges and priorities, resulting in this integrated, comprehensivereference volume on the state of health in developing countries. |
| direct observation therapy for tb: Tuberculosis in the Workplace Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee on Regulating Occupational Exposure to Tuberculosis, 2001-05-15 Before effective treatments were introduced in the 1950s, tuberculosis was a leading cause of death and disability in the United States. Health care workers were at particular risk. Although the occupational risk of tuberculosis has been declining in recent years, this new book from the Institute of Medicine concludes that vigilance in tuberculosis control is still needed in workplaces and communities. Tuberculosis in the Workplace reviews evidence about the effectiveness of control measuresâ€such as those recommended by the Centers for Disease Control and Preventionâ€intended to prevent transmission of tuberculosis in health care and other workplaces. It discusses whether proposed regulations from the Occupational Safety and Health Administration would likely increase or sustain compliance with effective control measures and would allow adequate flexibility to adapt measures to the degree of risk facing workers. |
| direct observation therapy for tb: Global Tuberculosis Control World Health Organization, 2008 WHO's twelfth annual report on global tuberculosis control in a series that started in 1997. |
| direct observation therapy for tb: Tuberculosis in Adults and Children Dorothee Heemskerk, Maxine Caws, Ben Marais, Jeremy Farrar, 2015-07-17 This work contains updated and clinically relevant information about tuberculosis. It is aimed at providing a succinct overview of history and disease epidemiology, clinical presentation and the most recent scientific developments in the field of tuberculosis research, with an emphasis on diagnosis and treatment. It may serve as a practical resource for students, clinicians and researchers who work in the field of infectious diseases. |
| direct observation therapy for tb: Guidelines for the Programmatic Management of Drug-resistant Tuberculosis World Health Organization, 2008 The emergence of extensively drug-resistant strains of tuberculosis, especially in countries with a high prevalence of human immunodeficiency virus, is a serious threat to global public health and jeopardizes efforts to effectively control the disease. This publication offers updated recommendations for the diagnosis and management of drug-resistant tuberculosis in a variety of geographical, economic and social settings, and the recording of data that enables the monitoring and evaluation of programs.--Publisher's description. |
| direct observation therapy for tb: WHO consolidated guidelines on drug-resistant tuberculosis treatment World Health Organization, 2018-11-07 Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult to treat than drug-susceptible ones, and threaten global progress towards the targets set by the End TB Strategy of the World Health Organization (WHO). There is thus a critical need for evidence-based policy recommendations on the treatment and care of patients with DR-TB, based on the most recent and comprehensive evidence available. In this regard, the WHO consolidated guidelines on drug-resistant tuberculosis treatment fulfil the mandate of WHO to inform health professionals in Member States on how to improve treatment and care for patients with DR-TB. Between 2011 and 2018, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recommendations have been presented in several WHO documents and their associated annexes, including the WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update, issued by WHO in December 2018. The policy recommendations in each of these guidelines have been developed by WHO-convened Guideline Development Groups (GDGs), using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach to summarize the evidence, and formulate policy recommendations and accompanying remarks. The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, including longer and shorter regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care. |
| direct observation therapy for tb: Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children World Health Organization, 2015-02-05 It is estimated that one third of the world's population is infected with Mycobacterium tuberculosis (the bacterium that causes tuberculosis (TB)), and that each year, about 9 million people develop TB, of whom about 2 million die. Of the 9 million annual TB cases, about 1 million (11%) occur in children (under 15 years of age). Of these childhood cases, 75% occur annually in 22 high-burden countries that together account for 80% of the world's estimated incident cases. In countries worldwide, the reported percentage of all TB cases occurring in children varies from 3% to more than 25%. The Stop TB Strategy, which builds on the DOTS strategy developed by the World Health Organization (WHO) and the International Union Against TB and Lung Disease, has a critical role in reducing the worldwide burden of disease and thus in protecting children from infection and disease. The management of children with TB should be in line with the Stop TB Strategy, taking into consideration the particular epidemiology and clinical presentation of TB in children. These consensus guidelines were produced to help the National Tuberculosis Programmes on the management of tuberculosis in children. |
| direct observation therapy for tb: Netter's Infectious Diseases - E-Book Elaine C. Jong, Dennis L. Stevens, 2021-03-19 Widely used by students, residents, generalists, and specialists, Netter's Infectious Diseases, 2nd Edition delivers must-know information on infectious diseases in a highly illustrated, easily accessible format. Concise visual overviews of essential topics provide a convenient, trustworthy way to review the basics of a given infectious disease or issue or to share with patients or staff. Drs. Elaine Jong and Dennis Stevens cover the wide spectrum of illness and disease in this complex field using memorable illustrations by world-renowned artist Frank H. Netter and others, offering a time-saving, authoritative look at infectious disease risk factors, clinical presentations, pathophysiology, and more. - Covers major conditions and problems such as vaccine-preventable diseases, drug-resistant staph, community acquired pneumonia, surgical infections, pyelonephritis, viral hepatitis, and sexually transmitted infections—and provides updated approaches to diagnosis, treatment, prevention, and standards of care. - Includes new clinical vignettes added to most chapters - Provides updated and expanded coverage of emerging infectious diseases such as multidrug resistant tuberculosis (MDR-TB), neuroangiostrongyliasis (rat lungworm disease), Ebola virus, Severe Acute Respiratory Disease (SARS), Middle East Respiratory Syndrome (MERS), Coronavirus Infectious Disease-2019 (COVID-19), and novel influenza viruses including public health concerns. - Covers vector-borne diseases including malaria, yellow fever, Zika infections and congenital Zika syndrome, West Nile fever, Lyme disease, tick-borne encephalitis, and Chagas disease plus others. - New chapters on travelers' diarrhea, cholera, and primary amebic meningoencephalitis debut in the section on international travel and outdoor activities. - Contains memorable parasite life cycles and unforgettable parasite infection clinical vignettes. - Features unparalleled illustrations by Drs. Frank H. Netter, Carlos Machado, and others, as well as radiologic images. - Provides 24 printable patient education brochures in the digital ebook. |
| direct observation therapy for tb: Toman's Tuberculosis K. Toman, World Health Organization, 2004-06-23 This is the second edition of a reference work aimed at all those concerned with dealing with tuberculosis control in developing countries. The book follows in the tradition of Kurt Toman's original work in this field, with the text set out in a question and answer format, grouped under three headings: case detection; treatment, and monitoring. The threat of tuberculosis is still potent, with two million deaths globally. This new edition, containing contributions from a number of experts in this field, addresses the resurgence of tuberculosis, and the emergence of multidrug-resistant bacilli, and the growth of HIV-infected individuals with tuberculosis, as well as recent scientific developments. |
| direct observation therapy for tb: Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis World Health Organization, 2015-04-20 This 2011 update of Guidelines for the programmatic management of drug-resistant tuberculosis is intended as a tool for use by public health professionals working in response to the Sixty-second World Health Assembly's resolution on prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Resolution WHA62.15, adopted in 2009, calls on Member States to develop a comprehensive framework for the management and care of patients with drug-resistant TB. The recommendations contained in these guidelines address the most topical questions concerning the programmatic management of drug-resistant TB: case-finding, multidrug resistance, treatment regimens, monitoring the response to treatment, and selecting models of care. The guidelines primarily target staff and medical practitioners working in TB treatment and control, and partners and organizations providing technical and financial support for care of drug-resistant TB in settings where resources are limited. |
| direct observation therapy for tb: HIV-related TB. , 1993 |
| direct observation therapy for tb: Ending Neglect Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee on the Elimination of Tuberculosis in the United States, 2000-08-31 Tuberculosis emerged as an epidemic in the 1600s, began to decline as sanitation improved in the 19th century, and retreated further when effective therapy was developed in the 1950s. TB was virtually forgotten until a recent resurgence in the U.S. and around the worldâ€ominously, in forms resistant to commonly used medicines. What must the nation do to eliminate TB? The distinguished committee from the Institute of Medicine offers recommendations in the key areas of epidemiology and prevention, diagnosis and treatment, funding and organization of public initiatives, and the U.S. role worldwide. The panel also focuses on how to mobilize policy makers and the public to effective action. The book provides important background on the pathology of tuberculosis, its history and status in the U.S., and the public and private response. The committee explains how the U.S. can act with both self-interest and humanitarianism in addressing the worldwide incidence of TB. |
| direct observation therapy for tb: Comprehensive Handbook of Alcohol Related Pathology Victor R. Preedy, Ronald Ross Watson, 2004-12-24 This comprehensive handbook is a one-stop-shop for all researchers involved in the field of alcohol-related harm at the whole body or cellular level. Over 100 chapters provide abundant information of a wide range of topics that extend from the evolutionary aspects of alcohol consumption and the prevalence of alcohol misuse to programmed cell death. Each chapter is highly illustrated with tables and figures making this a valuable reference for students, clinicians and researchers alike. *Over 100 chapters conveniently divided into 3 sections *Represents a 'one-stop-shop' of information with suitable indexing of the various pathways and processes *Each chapter is highly illustrated with tables as well as figures |
| direct observation therapy for tb: Antibiotic and Chemotherapy Roger G. Finch, 2003 The completely revised and updated New Edition of this respected resource presents globally-relevant coverage of all types of antimicrobial agents used in human medicine, providing authoritative guidance on the principles and practice of antimicrobial chemotherapy. In addition to full coverage of every commonly used antibiotic agent, it includes complete coverage of all antiviral, antiprotozoan and anthelminthic agents. And, its unique 3-part structure makes it easy to locate information: Part I covers general aspects of treatment; Part II reviews every agent, including antimicrobial activity, pharmacokinetics, clinical use, and available preparations; Part III details the treatment of particular infections. Discusses the increasing problem of multi-drug resistance and the wide range of new antiviral therapies now available for the treatment of HIV and other viral infections. Reviews all of the new antimicrobial agents in detail. Features more clinically focused sections on Pharmacokinetics. Details new antifungal therapies, including voriconazole, liposomal, and amphotericin B. Presents new tables on major drug interactions, placental transfer, and concentrations of agents in breast milk. Features new sections on liver failure, drug development and licensing, and the implications of xenotransplantation. Presents expanded coverage of Quinolone as well as new antimalarial combination therapies. Offers cross-references to key web sites, for up-to-date information on treatment and drug resistance. |
| direct observation therapy for tb: Interventions for Tuberculosis Control and Elimination Hans L. Rieder, 2002 |
| direct observation therapy for tb: Healthcare Access Umar Bacha, Urška Rozman, Sonja Šostar Turk, 2020-05-27 Healthcare Access - Regional Overviews is a compilation of ten chapters consisting of case studies, research works, reviews, and expert opinions providing insight on the previous and current developments in the field of hygiene and infection control with practices to prevent or minimize the spread of infectious diseases. The book also addresses the status and healthcare access of the most neglected segments in less developed countries. All chapters are written by global researchers are edited by experts in the field. The information presented in this work can be replicated at different levels to accelerate timely and quality healthcare services. |
| direct observation therapy for tb: Drug Monitoring and Clinical Chemistry Georg Hempel, 2004-05-15 Drug Monitoring and Clinical Chemistry, the 5th volume in the Handbook of Analytical Separations series, gives an overview about methods to analyse drugs in biological fluids. The most widely used methods to analyse drugs in biological fluids. i.e. chromatographic methods, CE and immunoassays are described in detail. For important drugs, an overview about the methods available and a comparison of the techniques should be given to enable the reader to choose the right method depending on laboratory equipment, staff, the aim of the investigation etc. Other general aspects important for conducting therapeutic drug monitoring or pharmacokinetics studies are also covered, i.e. sample preparation, validation of the analytical methods and pharmacokinetic methods for interpreting the data. Areas where therapeutic drug monitoring is used frequently such as antibiotics, immunosuppressant drugs, antipsychotic and anticancer drugs will be discussed in detail. In addition, the important field of phenotyping and genotyping for therapy optimisation with special focus on real-life applications is also covered. The book contains important information for analyst working on drug analysis in clinical chemistry, hospital pharmacists involved in therapeutic drug monitoring, other pharmacists, chemists or physicians working on pharmacokinetic studies in industry or academia. In contrast to other books in this field, this book provides up-to-date information regarding both methodology and clinical applications. For the applications, only fields are described where therapeutic drug monitoring is used in clinical routine and provides benefit to the patients. - Overview of all important field where therapeutic drug monitoring is applied - All relevant analytical and computational methods are discussed - Written by experts with a lot of practical experience in the field |
| direct observation therapy for tb: Management of MDR-TB World Health Organization, 2009 Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are increasingly encountered in resource-limited settings. In the context of a national response to MDR- and XDR-TB, health workers in TB clinics (in district hospitals and some accredited health centers) will need to diagnose MDR-TB, initiate second-line anti-TB drugs, and monitor MDR-TB treatment. This Field Guide was created to help health workers carry out these tasks. It is a job aid that medical officers and TB nurses are meant to use frequently during the day for quick reference. It is based on the Emergency Update 2008 of Guidelines for Programmatic Management of Drug-resistant Tuberculosis, and may be considered a companion document to these guidelines. It also draws on the experience of the international health NGO Partners In Health (PIH) in many countries. This module should be introduced to health workers in the context of a training course with a strong emphasis on TB-HIV co-management. |
| direct observation therapy for tb: The Use of Bedaquiline in the Treatment of Multidrug-resistant Tuberculosis World Health Organization, 2015-04-20 WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far more expensive than those used to treat drug-susceptible TB. Globally, less than half of all patients who start MDR-TB therapy are treated successfully. For the first time in over 40 years, a new TB drug with a novel mechanism of action - bedaquiline- is available, and was granted accelerated approval by the United States Food and Drug Administration in December 2012. There is considerable interest in the potential of this drug to treat MDR-TB. However, information about this new drug remains limited. It has only been through two Phase IIb trials for safety and efficacy. The World Health Organization (WHO) is therefore issuing interim policy guidance. This interim guidance provides advice on the inclusion of bedaquiline in the combination therapy of MDR-TB in accordance with the existing WHO Guidelines for the Programmatic Management of Drug-resistant TB (2011 Update). |
| direct observation therapy for tb: Global Tuberculosis Report 2015 World Health Organization, 2015 Chapter 1. Introduction -- chapter 2. Disease burden and 2015 targets assessment -- chapter 3. TB case notifications and treatment outcomes -- chapter 4. Drug-resistant TB -- chapter 5. Diagnostics and laboratory strengthening -- chapter 6. Addressing the co-epidemics of TB and HIV -- chapter 7. Financing -- chapter 8. Research and development -- Annexes. |
| direct observation therapy for tb: Global Health and the Future Role of the United States National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Global Health, Committee on Global Health and the Future of the United States, 2017-10-05 While much progress has been made on achieving the Millenium Development Goals over the last decade, the number and complexity of global health challenges has persisted. Growing forces for globalization have increased the interconnectedness of the world and our interdependency on other countries, economies, and cultures. Monumental growth in international travel and trade have brought improved access to goods and services for many, but also carry ongoing and ever-present threats of zoonotic spillover and infectious disease outbreaks that threaten all. Global Health and the Future Role of the United States identifies global health priorities in light of current and emerging world threats. This report assesses the current global health landscape and how challenges, actions, and players have evolved over the last decade across a wide range of issues, and provides recommendations on how to increase responsiveness, coordination, and efficiency †both within the U.S. government and across the global health field. |
| direct observation therapy for tb: Adherence to Long-term Therapies Eduardo Sabaté, World Health Organization, 2003 This report is based on an exhaustive review of the published literature on the definitions, measurements, epidemiology, economics and interventions applied to nine chronic conditions and risk factors. |
| direct observation therapy for tb: Genital Tuberculosis Gita Ganguly Mukherjee, Satchidananda Tripathy, Sindhu Nandini Tripathy, 2010-02-28 |
| direct observation therapy for tb: Recommendations for Investigating Contacts of Persons with Infectious Tuberculosis in Low- and Middle-Income Countries World Health Organization, 2012 The main purpose of these recommendations is to assist national and local public health tuberculosis (TB) control programmes in low- and middle-income countries to develop and implement case finding among people exposed to infectious cases of TB. Systematic evaluation of people who have been exposed to potentially infectious cases of tuberculosis (TB) can be an efficient, targeted approach to intensified TB case finding that is within the purview of TB control programmes. There are, however, no comprehensive global recommendations for programmes. WHO, the International Union against Tuberculosis and Lung Disease and the International Standards for Tuberculosis Care all recommend that children under 5 years of age and persons living with HIV (PLHIV) who are exposed to infectious cases of TB be evaluated for active TB and considered for treatment of latent tuberculosis infection (LTBI) if active TB is excluded. With these exceptions, there are no recommendations at global level to: 1. define the epidemiological and programme conditions under which contact investigation is indicated;2. describe TB index patients on whom contact investigation should be focused;3. identify TB contacts who should be investigated (other than children under 5 years of age and PLHIV);and recommend the procedures to be used for identifying, screening and tracking TB contacts. The following recommendations are based on recent systematic reviews of the literature on contact investigation in low- and middle-income countries. |
| direct observation therapy for tb: Systematic Screening for Active Tuberculosis World Health Organization, 2013 There have been calls to revisit the experiences of TB screening campaigns that were widely applied in Europe and North America in the mid-20th century, as well as more recent experiences with TB screening in countries with a high burden of the disease, and to assess their possible relevance for TB care and prevention in the 21st century. In response, WHO has developed guidelines on screening for active TB. An extensive review of the evidence has been undertaken. The review suggests that screening, if done in the right way and targeting the right people, may reduce suffering and death, but the review also highlights several reasons to be cautious. As discussed in detail in this book, there is a need to balance potential benefits against the risks and costs of screening; this conclusion is mirrored by the history of TB screening. This publication presents the first comprehensive assessment by WHO of the appropriateness of screening for active TB since the recommendations made in 1974 by the Expert Committee. However, the relative effectiveness and cost effectiveness of screening remain uncertain, a point that is underscored by the systematic reviews presented in this guideline. Evidence suggests that some risk groups should always be screened, whereas the prioritization of other risk groups as well as the choice of screening approach depend on the epidemiology, the health-system context, and the resources available. This book sets out basic principles for prioritizing risk groups and choosing a screening approach; it also emphasizes the importance of assessing the epidemiological situation, adapting approaches to local situations, integrating TB screening into other health-promotion activities, minimizing the risk of harm to individuals, and engaging in continual monitoring and evaluation. It calls for more and better research to assess the impact of screening and to develop and evaluate new screening tests and approaches. |
| direct observation therapy for tb: Zoonotic Tuberculosis Charles O. Thoen, James H. Steele, John B. Kaneene, 2014-02-12 Zoonotic Tuberculosis: Mycobacterium bovis and Other Pathogenic Mycobacteria, Third Edition is a comprehensive review of the state of the art in the control and elimination of infections caused by Mycobacterium tuberculosis complex in animals and humans. This update to the most complete and current reference available on Mycobacterium bovis includes new coverage of the latest molecular techniques; more information on human infection and One Health; updates to the information on the International Union Against Tuberculosis and Lung Disease (IUATLD), the World Health Organization (WHO), Pan American Health Organization (PAHO), and the United States Department of Agriculture’s (USDA) National Tuberculosis Eradication Program; and coverage of additional African countries. The Third Edition upholds the book’s reputation as a truly global resource on M. bovis. Written by an international list of tuberculosis experts, chapters cover the status of tuberculosis in many regions throughout the world and deal with issues related to the detection, spread, and control of Mycobacterium bovis, as well as the economic impact of outbreaks. Zoonotic Tuberculosis: Mycobacterium bovis and Other Pathogenic Mycobacteria offers valuable information for public health officials, medical doctors, state and federal regulatory veterinarians, veterinary practitioners, and animal caretakers. |
| direct observation therapy for tb: Core Curriculum on Tuberculosis , 1991 |
| direct observation therapy for tb: Drug Interactions in Infectious Diseases Stephen C. Piscitelli, Keith A. Rodvold, Manjunath P. Pai, 2011-09-08 The revised and up-to-date third edition of Drug Interactions in Infectious Diseases delivers a text that will enhance your clinical knowledge of the complex mechanisms, risks, and consequences of drug interactions associated with antimicrobials, infection, and inflammation. The third edition features five new chapters that cover material not addressed in previous editions. These new chapters describe interactions with a number of drug classes such as non-HIV antiviral, antimalarial, antiparasitic, antihelmintic, macrolide, azalide and ketolide agents. A novel chapter on probe cocktail studies has been included to highlight an important research tool for drug development. These chapters address material that cannot be retrieved easily in the medical literature. The highly acclaimed food-drug interactions as well as the study design and analysis chapters remain definitive references. The newly written drug-cytokine interaction highlights the need for our improved understanding of the complex interrelationship of acute infection, inflammation, and the risk of drug interactions. Informative tables on specific drug-drug interactions are provided throughout the chapters as a quick clinical resource. The Third Edition of Drug Interactions in Infectious Diseases is a distillation of relevant drug interactions associated with antimicrobials, infection, and inflammation. This concise review of the mechanisms and strategies to manage drug interactions should be valuable to all health care practitioners. Features • Definitive reference source of up-to-date information on antimicrobial drug interactions • Informative tables on the degree of interaction for specific antimicrobial agents • In-depth discussion of mechanisms and potential mechanistic pathways of interaction • New chapters on non-HIV antiviral, antimalarial, antiparasitic, and macrolide, azalide and ketolide agents • New chapter on probe-cocktail studies as a research tool to study drug-drug interactions • Inclusion of new antimicrobial agents and their associated drug interactions • First rate chapters on study design and analysis, and drug-food interactions • A fresh perspective on drug-cytokine interactions • Authoritative chapter on regulatory considerations of drug interactions during drug development |
| direct observation therapy for tb: Clinical Tuberculosis John Crofton, Norman Horne, Frederick John William Miller, 1992 |
| direct observation therapy for tb: Global Tuberculosis Report 2014 World Health Organization, 2014 Some volumes for 2014 includes CD-ROM for 2014 key indicators. |
| direct observation therapy for tb: American Academy of Pediatrics Textbook of Pediatric Care Jane Meschan Foy, 2016-03-31 The definitive manual of pediatric medicine - completely updated with 75 new chapters and e-book access. |
| direct observation therapy for tb: Global Tuberculosis Report 2017 World Health Organization, 2017-12-13 WHO's Global Tuberculosis Report provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in care and prevention at global, regional and country levels. This is done in the context of recommended global TB strategies and associated targets, and broader development goals. For the period 2016-2035, these are WHO's End TB Strategy and the United Nations' (UN) Sustainable Development Goals (SDGs), which share a common aim: to end the global TB epidemic. The main data sources for the report are annual rounds of global TB data collection implemented by WHO's Global TB Program since 1995 and databases maintained by other WHO departments, UNAIDS and the World Bank. In WHO's 2017 round of global TB data collection, 201 countries and territories that account for over 99% of the world's population and TB cases reported data. |
| direct observation therapy for tb: New Topics in Tuberculosis Research Donald D. Spiegelburg, 2007 Tuberculosis, the disease that the World Health Organization has recently declared a global emergency, was supposedly defeated by antibiotics half a century ago. It has returned in a highly contagious and fatal new form that cannot be treated with conventional drugs. Multidrug-resistant TB (MDR-TB), could cause some 10 million deaths over the next decade and is thriving in the overcrowded prisons of the former Soviet Union. The virtual collapse of the world's borders means that refugees, tourists, immigrants, business travellers, and others can spread the TB bacillus very efficiently. London, for example, has experienced a 100 per cent increase in reported cases in the past 10 years. This book covers all aspects of the disease: epidemiology, microbiology, diagnosis, treatment, control and prevention. Leading research is presented from centres around the world. |
| direct observation therapy for tb: Global Tuberculosis Report 2016 World Health Organization, 2016 This global tuberculosis report is the first to be produced in the era of the SDGs and the End TB Strategy. It provides an assessment of the TB epidemic and progress in TB diagnosis, treatment, and prevention efforts as well as an overview of TB-specific financing and research. It also discusses the broader agenda of universal health coverage, social protection, and other SDGs that have an impact on health. Data was available for 202 countries and territories that account for over 99% of the world's population and TB cases. |
| direct observation therapy for tb: Treatment of Tuberculosis World Health Organization, 2010 Previous editions had different title: Treatment of tuberculosis: guidelines for national programmes. |
DirecTV login | DIRECTV Community Forums
May 9, 2024 · I have a third television in my home and downloaded the direct TV stream app on a firestick. After logging in with the correct credentials I am prompted with a screen to choose a …
DIRECTV Community Forums
The DIRECTV Support Community Forums – Find answers to questions about DIRECTV’s products and services. Get tech support, share tips and tricks, or contact DIRECTV for account …
Can’t log into direct tv stream app care code 902
Jul 23, 2024 · As mentioned in OP I literally just made a direct TV account maybe 30/45 mins before this post. But it kept coming up WiFi/connection issues under posts and via google. I …
termination fee - DIRECTV Community Forums
Dec 3, 2024 · I am also thinking i may want to terminate my services for internet and phone, all of which are long standing with ATT. This is a very disappointing rule regarding Direct …
DIRECTV Outage and Error Help & Information - DIRECTV Com…
Protection Plan. Get the ultimate coverage for your entire DIRECTV® System at home from $8.99/mo. …
DirecTV login | DIRECTV Community Forums
May 9, 2024 · I have a third television in my home and downloaded the direct TV stream app on a firestick. After logging in with the correct credentials I am prompted with a screen to choose a …
DIRECTV Community Forums
The DIRECTV Support Community Forums – Find answers to questions about DIRECTV’s products and services. Get tech support, share tips and tricks, or contact DIRECTV for …
Can’t log into direct tv stream app care code 902
Jul 23, 2024 · As mentioned in OP I literally just made a direct TV account maybe 30/45 mins before this post. But it kept coming up WiFi/connection issues under posts and via google. I …
termination fee - DIRECTV Community Forums
Dec 3, 2024 · I am also thinking i may want to terminate my services for internet and phone, all of which are long standing with ATT. This is a very disappointing rule regarding Direct TV. Would …
DIRECTV Outage and Error Help & Information - DIRECTV …
Protection Plan. Get the ultimate coverage for your entire DIRECTV® System at home from $8.99/mo. Equipment upgrade req's new 24-month agreement.
Set up a new account for direct.com my community - DIRECTV …
Jun 24, 2023 · We're excited to be your entertainment provider and appreciate your attention to our service. Check our package information and prices here DIRECTV TV Packages Via …
Tv suddenly has no signal | DIRECTV Community Forums
Jun 23, 2020 · Regardless it’s a tv issue not a direct tv issue -------------------INCLUDED IN EACH POST FOR CLARIFICATION______ While AT&T employees do look at forum posts from time …
Direct TV App no longer working | DIRECTV Community Forums
Jan 30, 2025 · Typical foreign support! I’ve called 2 times. Once to a customer service rep, who followed the laid out plan for problems.
Find out how to return your DIRECTV equipment
Apr 3, 2023 · If we direct you to FedEx or UPS It's fast and easy and no packing is necessary. Just bring your unboxed equipment and 9-digit account number to a company-owned FedEx …
Closed Captioning - DIRECTV Community Forums
Sep 11, 2023 · I am new to DirectTV stream, Coming from U-Verse. I am trying to find a shortcut method for turning Closed Captioning on and off. Google Assistant voice is …
